Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree - 2Artemis II live updates: NASA's historic moon mission set to make lunar flyby today
- 3Island Travel Guide: Must-Visit Objections for 2024
- 46 Top Computer game Control center
- 5The most effective method to Connect Successfully with Teachers in a Web based Setting
- NASA releases stunning new images captured by the Artemis II moon mission, including 'Earthset' and a solar eclipse from space
- Authentic Urban areas: Rich Legacy and Lively Societies
- 'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- ‘Extraordinary’ Iron Age war trumpet uncovered in England
- At least 11 killed in South Africa mass shooting
- Over 1,800 killed since junta seized power in Burkina Faso, rights group says
- A Manual for Nations to Head out To
- Humpback whale stranded on Germany's Baltic coast frees itself
- Tech Devices 2023: The Most blazing Arrivals of the Year
